Related references
Note: Only part of the references are listed.Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials
Dony Patel et al.
VALUE IN HEALTH (2021)
Real-world evidence and regulatory drug approval
Michael J. Raphael et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Use of Real-world Data for New Drug Applications and Line Extensions
Winona R. Bolislis et al.
CLINICAL THERAPEUTICS (2020)
Synthetic and External Controls in Clinical Trials - A Primer for Researchers
Kristian Thorlund et al.
CLINICAL EPIDEMIOLOGY (2020)
Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms
Mehmet Burcu et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
Methods for external control groups for single arm trials orlong-termuncontrolled extensions to randomized clinical trials
John D. Seeger et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)
A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness
Michael Anderson et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2019)
Characteristics of non-randomised studies using comparisons with external controls submitted for regulatory approval in the USA and Europe: a systematic review
Sarah Goring et al.
BMJ OPEN (2019)
A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics A Review
Julia A. Beaver et al.
JAMA ONCOLOGY (2018)
AGENCY AGREEMENT IN HEALTH TECHNOLOGY ASSESSMENT REIMBURSEMENT DECISIONS
A. Jaksa et al.
VALUE IN HEALTH (2013)